SUPPORTING MATERIAL

Attitudes of Optometrists toward Artificial Intelligence for the Diagnosis of Retinal Disease: A cross-sectional mail-out survey

Sharon Ho^{1,2}, Gordon S. Doig^{1,2} and Angelica Ly^{1,2,3}

¹Centre for Eye Health, The University of New South Wales, Sydney, Australia. ²School of Optometry and Vision Science, The University of New South Wales, Sydney, Australia. ³Brien Holden Vision Institute, The University of New South Wales, Sydney, Australia.

Corresponding Author:

Dr. Angelica Ly Rupert Myers Building Gate 14 Barker Street, UNSW Kensington, 2052 Australia Email: a.ly@unsw.edu.au

Contents

| Figure s1. Survey Booklet |
|---|
| Table s1. Additional workplace characteristics. 11 |
| Table s2. Attitudes toward Advanced pattern recognition algorithms |
| Table s3. Attitudes toward Artificial Intelligence. 14 |
| Table s4. General comments on the use of Artificial Intelligence |
| Table s5. Attitudes toward the use of Artificial Intelligence in an alternative clinical scenario |
| Table s6. Univariate and multivariate analysis of factors influencing attitudes toward Artificial Intelligence. |
| |

Figure s1. Survey Booklet.





Attitudes of Primary Eye Care Clinicians toward Artificial Intelligence to support the diagnosis of Retinal Disease

SURVEY BOOKLET

HC Number: HC210014, Version dated 8 February 2021.



<u>General Instructions</u>: Please respond to all statements to the best of your ability in the order that they appear. Directions for completing individual sections are given throughout the survey where necessary. When you have completed the survey please return at your earliest convenience using the provided postage-paid envelope. All responses collected through this survey will be completely anonymous and confidential.

Section 1: Participant characteristics

Unless otherwise stated, please provide one response per question.

| Gender 1.1 Which gender do you identify with? | a. Male b. Female c. Gender diverse |
|---|---|
| Age 1.2 What is your age? | |
| Experience 1.3 How many years (total full-time equivalent) have you have been practising in primary eye care? | |
| Workplace: general 1.4 In which state or territory is your main workplace located? | □ a. NSW □ d. QLD □ g. WA □ b. ACT □ e. NT □ h. SA □ c. VIC □ f. TAS |
| 1.5 Where is your main workplace located? Provide the postcode. | |
| 1.6 What is your main work setting? | a. Public hospital b. Private hospital c. Community health centre d. Educational institution e. Corporate practice f. Independent practice |
| 1.7 How is your main workplace funded? (Select all that apply) | a. Medicare bulk billing b. Medicare non-bulk billing c. Private health insurance d. Private spectacles sales e. Private contact lens sales f. Not-for-profit organisations g. State government h. Other; please specify |

Survey continues on next page...

HC Number: HC210014, Version dated 8 February 2021.



| 1.8 How many optometrists do you work alongside on a regular day at your main workplace, INCLUDING YOURSELF? | |
|---|--|
| 1.9 How many patients do you see on an average day at your main workplace? | |
| 1.10 How many patients with retinal disease do you see on an average day at your main workplace? (Include retinal disease of any severity, and conditions such as vitreomacular traction and pigmented lesions. Exclude glaucoma affecting the retinal ganglion cell layer, and other optic neuropathies) | |
| 1.11 How easy or difficult is it for you to obtain the ophthalmology services you need at your main workplace? | a. Very easy b. Easy c. Moderate d. Difficult e. Very difficult |
| <u>Workplace: technology</u> 1.12 What ophthalmic devices, if any, are used when providing care to patients at your main workplace? (Select all that apply) | a. Fundus camera b. Optical coherence tomography (OCT) c. Ultra-wide field imaging d. Fundus autofluorescence e. Visual field f. OCT-angiography g. Non-contact tonometry or Icare tonometer h. Digital letter chart i. Keratometer j. Pachymeter k. Corneal topographer l. Autorefractor m. Autophoropter n. Slitlamp camera o. None of the above |
| 1.13 What form of medical record system do you use at your main workplace? | a. Paper-basedb. Electronic |

HC Number: HC210014, Version dated 8 February 2021.



| 1.14 What computerised systems, if any, are used at your main workplace? (Select all that apply) | a. Electronic patient appointment system b. Online patient booking system, whereby a patient can book an appointment directly c. Billing tracking software (e.g. for Medicare claims, dispensing sales) d. Electronic therapeutic prescribing e. Dedicated electronic referral/report management system f. Practice management software (e.g. Sunix, Optomate) g. None of the above |
|---|---|
| 1.15 In what capacity are you involved in decisions related to the use of digital health technologies at your main workplace? | a. I have a major role in decisions b. I am able to influence decisions c. I have no role in decisions |
| 1.16 Who oversees the IT systems at your main workplace? (Select all that apply) | a. External, contracted IT service provider b. Practice manager c. Administrative staff member d. Colleague e. Myself f. Other; please specify g. Don't know |

HC Number: HC210014, Version dated 8 February 2021.



Section 2: Survey Part A

Please indicate the extent to which you agree or disagree with the following statements as they apply to primary eye care. For all statements:

 Consider the application of advanced pattern recognition algorithms in identifying important features in OCT scan data to classify images and thereby aid the diagnosis of retinal disease.

For the remainder of the survey, disregard the influence your employer and other colleagues may have on IT decisions and respond based on **YOUR** views alone. Select one response per statement.

| | Strongly disagree | Disagree | Neither agree nor disagree | Agree | Strongly agree |
|--|----------------------|----------|----------------------------------|-------|-------------------|
| 2.1 In the future, I see myself using advanced pattern recognition algorithms as tools to aid the diagnosis of retinal disease | | | | | |
| 2.2 Increased use of advanced pattern recognition algorithms to aid the diagnosis of retinal disease excites me | | | | | |

Once you begin Section 3, please do not change your responses to Section 2.

Section 3: Survey Part B

Please indicate the extent to which you agree or disagree with the following statements as they apply to primary eye care. For all statements:

- Artificial intelligence (AI) is defined as systems that incorporate computer-based technologies that mimic human thought processes to augment clinical decision-making. Clinical decision-making is defined as the process by which patient data is gathered, interpreted and evaluated by the clinician in order to formulate a diagnosis.
- Consider Clinical Scenario 1: During an examination, a clinician suspects a patient to have a retinal disease based on the case history and routine pre-testing but is uncertain of the diagnosis. The clinician may then process the patient's OCT scan data using AI which provides a likely diagnosis.

| | Strongly disagree | Disagree | Neither agree nor disagree | Agree | Strongly agree |
|--|----------------------|----------|----------------------------------|-------|-------------------|
| AI application | | | | | |
| 3.1 In the future, I see myself using AI as a tool to aid the diagnosis of retinal disease | | | | | |
| 3.2 In the future, I see myself using AI as a learning tool to improve my own diagnostic abilities | | | | | |

Survey continues on next page...

HC Number: HC210014, Version dated 8 February 2021



| | Strongly disagree | Disagree | Neither agree nor disagree | Agree | Strongly agree |
|--|----------------------|----------|----------------------------------|-------|-------------------|
| 3.3 In the future, I believe there will be an overall need for AI in primary eye care | | | | | |
| AI benefits | | | | | |
| 3.4 In the future, I see myself using AI if it is proven to be more accurate than me | | | | | |
| 3.5 In the future, I see myself using AI if it is proven to save me time | | | | | |
| 3.6 In the future, I see myself using AI if it is proven to be more economically viable than my current diagnostic processes | | | | | |
| 3.7 In the future, I see myself using AI if it is proven to benefit my patients through more accessible healthcare | | | | | |
| 3.8 In the future, I see myself using AI if it is proven to be more reliable than me | | | | | |
| 3.9 In the future, I see myself using AI if it will fit into my clinical workflow | | | | | |
| 3.10 In the future, I see myself using AI if it will be easy to learn to use | | | | | |
| AI validation | | | | | |
| 3.11 Validation of the clinical effectiveness of AI through higher quality (randomised controlled trials) rather than lower quality (retrospective trials) studies is necessary for me to use it in the future | | | | | |
| 3.12 Validation of the accuracy of AI using a retinal specialist panel reference standard is necessary for me to use it in the future | | | | | |
| 3.13 Validation of the accuracy of AI using a general optometrist panel reference standard is necessary for me to use it in the future | | | | | |
| 3.14 Validation of AI on a patient population that resembles my clinical practice is necessary for me to use it in the future | | | | | |

HC Number: HC210014, Version dated 8 February 2021





| | Neither | | | | | | |
|--|----------------------|----------|-----------------------|-------|-------------------|--|--|
| | Strongly disagree | Disagree | agree nor disagree | Agree | Strongly agree | | |
| 3.15 Government approval of AI is necessary for me to use it in the future | | | | | | | |
| AI and clinicians | | | | | | | |
| 3.16 In the future, I see myself using AI if such automated processes surpass human clinician involvement in clinical decision- making | | | | | | | |
| 3.17 Increased use of AI to aid the diagnosis of retinal disease excites me | | | | | | | |
| 3.18 Increased dependence on AI resulting in a relative neglect of my clinical skills will limit my use of AI | | | | | | | |
| AI and patients | | | | | | | |
| 3.19 Informing patients about the use of AI is necessary for me to use it in the future | | | | | | | |
| 3.20 Informing patients of all AI-derived results related to their care is necessary for me to use AI in the future | | | | | | | |
| AI and conformity | | | | | | | |
| 3.21 In the future, I see myself using AI if my peers advise me to do so | | | | | | | |
| 3.22 In the future, I see myself using AI if most of my peers are using it | | | | | | | |
| 3.23 In the future, I see myself using AI if my patient requests that I do | | | | | | | |
| AI responsibilities: Consider the situation where, following Clinical Scenario 1, the clinician makes a diagnosis based on the AI solution. The diagnosis is then declared incorrect by an ophthalmologist, and the patient decides to take legal action against the primary care clinician. | | | | | | | |
| 3.24 In the future, I see myself using AI if clinicians bear sole medicolegal responsibility for the patient diagnosis. (Note: at the other end of the scale, developers of the AI bear sole medicolegal responsibility for the patient diagnosis) | | | | | | | |

HC Number: HC210014, Version dated 8 February 2021



Section 4: Survey Part C

Please indicate the extent to which you agree or disagree with the following statements as they apply to primary eye care. For all statements:

Consider Clinical Scenario 2: During an examination, a clinician suspects a patient to have a retinal disease based on the case history and routine pre-testing but is uncertain of the diagnosis. The clinician makes a tentative diagnosis for the patient. At the end of the day, the clinician selects the patients for which an AI-derived diagnosis is desired, and a system is run overnight to process the OCT scan data of the selected patients using AI which provides a likely diagnosis for each case the following morning. The clinician may then compare their tentative diagnosis to the AI-derived diagnosis, and adjust as required.

| | Strongly disagree | Disagree | Neither agree nor disagree | Agree | Strongly agree |
|--|----------------------|----------|----------------------------------|-------|-------------------|
| 4.1 In the future, I see myself using AI as a tool to aid the diagnosis of retinal disease | | | | | |
| 4.2 In the future, I see myself using AI as a learning tool to improve my own diagnostic abilities | | | | | |
| 4.3 Increased use of AI to aid the diagnosis of retinal disease excites me | | | | | |

5. Any other comments?

END OF SURVEY

Thank you for taking the time to participate in our study. Please ensure you have responded to <u>all</u> <u>statements</u>, then return this Survey Booklet at your earliest convenience using the postage-paid envelope provided. If you have indicated you would like to receive a copy of the research results on the Consent Form, please also return it along with this completed Survey Booklet.

HC Number: HC210014, Version dated 8 February 2021

Table s1. Additional workplace characteristics.

| Variable | Result |
|---|-----------------|
| General workplace characteristics | |
| Location (Australian state/territory) | |
| New South Wales | 36.8% (49/133) |
| Victoria | 27.1% (36/133) |
| Queensland | 17.3% (23/133) |
| Western Australia | 7.5% (10/133) |
| South Australia | 5.3% (7/133) |
| Australian Capital Territory | 3.0% (4/133) |
| Tasmania | 2.3% (3/133) |
| Northern Territory | 0.8% (1/133) |
| Location (geographical classification category) ⁺ | |
| MM1 | 55.6% (74/133) |
| MM3 | 15.8% (21/133) |
| MM2 | 12.0% (16/133) |
| MM4 | 10.5% (14/133) |
| MM5 | 4.5% (6/133) |
| MM6 | 1.5% (2/133) |
| MM7 | 0% (0/133) |
| Sources of funding include (may have reported >1) | |
| Private spectacle sales | 95.5% (127/133) |
| Private contact lens sales | 88.7% (118/133) |
| Medicare bulk billing | 88.0% (117/133) |
| Private health insurance | 85.0% (113/133) |
| Medicare non-bulk billing | 47.4% (63/133) |
| State government | 9.8% (13/133) |
| Not-for-profit organisations | 3.8% (5/133) |
| Other | 2.3% (3/133) |
| Optometrists working per day, mean (SD) | 1.9 (1.8) |
| Patients seen per day, mean (SD) | 12.5 (5.2) |
| Patients with retinal disease seen per day, mean (SD) | 2.4 (1.8) |
| Level of accessibility to ophthalmology services | |
| Very easy | 37.6% (50/133) |
| Easy | 35.3% (47/133) |
| Moderate | 22.6% (30/133) |
| Difficult | 2.3% (3/133) |
| Very difficult | 2.3% (3/133) |
| Technology-related workplace characteristics | |
| Ophthalmic devices used (may use >1) | |
| Visual field | 99.2% (132/133) |
| Fundus camera | 90.2% (120/133) |
| Digital letter chart | 86.5% (115/133) |
| Non-contact tonometry/Icare | 82.0% (109/133) |
| Optical coherence tomography | 75.9% (101/133) |
| Keratometer | 66.9% (89/133) |
| Autorefractor | 60.2% (80/133) |
| Pachymeter | 57.9% (77/133) |
| Corneal topographer | 48.9% (65/133) |
| Slitlamp camera | 45.1% (60/133) |
| Ultra-wide field imaging | 33.1% (44/133) |
| Fundus autofluorescence | 31.6% (42/133) |
| Autophoropter | 26.3% (35/133) |
| Optical coherence tomography angiography | 10.5% (14/133) |
| None | 0% (0/133) |
| Computerised systems used (may use >1) | (-,, |
| | 89.5% (119/133) |
| | |
| Practice management software | |
| Practice management software Electronic patient appointment system | 85.7% (114/133) |
| Practice management software | |

| Electronic therapeutic prescribing | 30.8% (41/133) |
|--|----------------|
| None | 3.0% (4/133) |
| | 5.0% (4/133) |
| Number of computerised systems used | |
| Five | 33.1% (44/133) |
| Four | 21.1% (28/133) |
| Three | 17.3% (23/133) |
| Six | 10.5% (14/133) |
| Two | 9.0% (12/133) |
| One | 6.0% (8/133) |
| None | 3.0% (4/133) |
| Level of involvement in decisions related to the use of digital health | technologies |
| Major role | 47.4% (63/133) |
| Influential role | 31.6% (42/133) |
| No role | 21.1% (28/133) |
| Party that oversees the IT systems (may have reported >1) | |
| External contracted IT service provider | 67.7% (90/133) |
| Self | 27.1% (36/133) |
| Practice manager | 24.1% (32/133) |
| Administrative staff | 13.5% (18/133) |
| Colleague | 12.8% (17/133) |
| Other | 6.0% (8/133) |
| Don't know | 5.3% (7/133) |

⁺Locations classified according to the Australian government's Modified Monash Model for measuring remoteness and population size.

Abbreviations: MM; Modified Monash, SD; Standard deviation.

Table s2. Attitudes toward Advanced pattern recognition algorithms.

Reported extent to which respondents agreed or disagreed with statements concerning the use of AI which employed the term "advanced pattern recognition algorithms" instead of "AI". Allowable responses were: Strongly disagree (score 1), Disagree (score 2), Neither agree nor disagree (score 3), Agree (score 4), Strongly agree (score 5).

| Question number & Statement | Ranked score, | % (n/N) selected each category | | | | | |
|--|----------------------|--------------------------------|----------------|------------------|------------------|-----------------|--|
| | mean (SD) | 1 | 2 | 3 | 4 | 5 | |
| In the future, I see myself using advanced pattern | recognition algorith | ms as | | | | | |
| 2.1 Tools to aid the diagnosis of retinal disease | 4.0 (0.8) | 0 (0/133) | 5.3 (7/133) | 16.5 (22/133) | 54.9 (73/133) | 23.3 (31/133 | |
| 2.2 Their increased use to aid the diagnosis of retinal disease excites me | 3.9 (0.8) | 0.8 (1/133) | 3.8 (5/133) | 22.6 (30/133) | 51.9 (69/133) | 21.1 (28/133 | |

Abbreviations: SD; Standard deviation.

Table s3. Attitudes toward Artificial Intelligence.

Reported extent to which respondents agreed or disagreed with statements concerning the use of artificial intelligence under Clinical Scenario 1, across its applications, benefits and validation. Allowable responses were: Strongly disagree (score 1), Disagree (score 2), Neither agree nor disagree (score 3), Agree (score 4), Strongly agree (score 5).

| Question number 8 Statement | Ranked score, mean (SD) | % (n/N) selected each category | | | | |
|--|----------------------------|--------------------------------|----------|----------|----------|---------|
| Question number & Statement | | 1 | 2 | 3 | 4 | 5 |
| AI Applications: In the future, I see myself using AI as. | | | | | | |
| 3.1 A tool to aid the diagnosis of retinal disease | 4.0.(0.8) | 0 | 4.5 | 17.3 | 56.4 | 21.8 |
| | 4.0 (0.8) | (0/133) | (6/133) | (23/133) | (75/133) | (29/133 |
| 3.2 A learning tool to improve my own diagnostic | 4.0 (0.7) | 0 | 2.3 | 18.8 | 56.4 | 22.6 |
| abilities | | (0/133) | (3/133) | (25/133) | (75/133) | (30/133 |
| 3.3 I believe there will be an overall need for AI in | 3.8 (0.8) | 0 | 5.3 | 27.1 | 46.6 | 21.1 |
| primary eye care | | (0/133) | (7/133) | (36/133) | (62/133) | (28/133 |
| Al Benefits: In the future, I see myself using AI if it is p | proven to | | | | | |
| | 4.1 (0.7) | 0 | 3.0 | 15.0 | 52.6 | 29.3 |
| 3.4 Be more accurate than me | | (0/133) | (4/133) | (20/133) | (70/133) | (39/133 |
| 256 | 4 1 (0 7) | 0 | 3.8 | 9.8 | 56.8 | 29.5 |
| 3.5 Save me time | 4.1 (0.7) | (0/132) | (5/132) | (13/132) | (75/132) | (39/132 |
| 3.6 Be more economically viable than my current | 4.0.(0.8) | 0 | 3.8 | 20.3 | 51.1 | 24.8 |
| diagnostic processes | 4.0 (0.8) | (0/133) | (5/133) | (27/133) | (68/133) | (33/133 |
| 3.7 Benefit my patients through more accessible | | 0 | 0.8 | 6.0 | 45.9 | 47.4 |
| healthcare | 4.4 (0.6) | (0/133) | (1/133) | (8/133) | (61/133) | (63/133 |
| 3.8 Be more reliable than me | 4.3 (0.6) | 0 | 0.8 | 6.8 | 54.1 | 38.3 |
| | | (0/133) | (1/133) | (9/133) | (72/133) | (51/133 |
| | 4.2 (0.6) | 0 | 0.8 | 8.3 | 60.9 | 30.1 |
| 3.9 Fit into my clinical workflow | | (0/133) | (1/133) | (11/133) | (81/133) | (40/133 |
| 2.10 Pa casu ta laarn ta usa | 4.1 (0.7) | 0 | 2.3 | 14.3 | 51.1 | 32.3 |
| 3.10 Be easy to learn to use | | (0/133) | (3/133) | (19/133) | (68/133) | (43/133 |
| Al Validation: For me to use AI in the future, it is nece | essary to validate | | | | | |
| 3.11 The clinical effectiveness of AI through higher | | 0 | 2.3 | 18.0 | 43.6 | 36.1 |
| quality (randomised controlled trials) rather than | 4.1 (0.8) | (0/133) | (3/133) | (24/133) | (58/133) | (48/133 |
| lower quality (retrospective trials) studies | | | | | | |
| 3.12 The accuracy of AI using a retinal specialist | 4.1 (0.7) | 0 | 1.5 | 15.8 | 54.1 | 28.6 |
| panel reference standard | (0 / | (0/133) | (2/133) | (21/133) | (72/133) | (38/133 |
| 3.13 The accuracy of AI using a general optometrist | 3.7 (0.9) | 0.8 | 6.8 | 31.6 | 42.1 | 18.8 |
| panel reference standard | | (1/133) | (9/133) | (42/133) | (56/133) | (25/133 |
| 3.14 AI on a patient population that resembles my | 3.6 (0.9) | 1.5 | 9.8 | 35.3 | 35.3 | 18.0 |
| clinical practice | | (2/133) | (13/133) | (47/133) | (47/133) | (24/133 |
| 3.15 Al through government approval | 3.4 (1.0) | 3.0 | 15.0 | 40.6 | 25.6 | 15.8 |
| | 3.4 (1.0) | (4/133) | (20/133) | (54/133) | (34/133) | (21/133 |
| | | | | | | |

Abbreviations: SD; Standard deviation, AI; Artificial intelligence.

Table s4. General comments on the use of Artificial Intelligence.

Open-ended feedback from respondents regarding the use of artificial intelligence in clinical optometric practice.

| No. | Comment |
|-----|--|
| 1 | Optometry is based on personable relationships. Computer recording in front of patients detracts from this. I would be |
| | careful not to detour from this in the future. Computers (AI) assist but I would be wary if they replace. |
| 2 | Objective analysis does not always see the complete patient picture. |
| 3 | I also believe it should be developed to predict/ID risk of cardiovascular and stroke!! |
| 4 | While AI is a helpful tool to assist diagnosis, it shouldn't replace entirely our existing ability to examine and diagnose. |
| 5 | Have had an OCT in practice since 2010, AI I see as an adjunct but diagnosis ultimately lies with the practitioner. |
| 6 | My key concern relating to AI is not its direct application to optometry or diagnostic accuracy but the potential to bypass |
| | optometry and refer to GPs or ophthalmology based solely on the acquisition of a scan. |
| 7 | AI would significantly assist in the diagnostic skills and capacity for optometry to more efficiently and accurately diagnose |
| | clinical conditions, minimising unnecessary overreferral as is currently being shown by corporate based optometrists. |
| 8 | Telehealth regionally for ophthalmology would be great also. |
| 9 | AI is an enhanced tool which would better enable to make more definitive diagnosis $ ightarrow$ I understand there is now AI |
| | programs that have been granted MDs, however the likelihood that patients will seek a program alone is unlikely. |
| 10 | I view AI diagnostics as simply another tool in the clinic. Ultimately the clinician is responsible for the patient. |
| 11 | Any technology that enhances patient care should be embraced. |
| 12 | Will use AI if available to add to clinical decision making, but not rely solely on it. If unsure, will still refer to ophthalmology |
| | for further tests if required. |
| 13 | We have come a long way in 40 years. I never stop learning! :) |
| 14 | One of our practices will be a trial for AI on diabetic retinopathy in the next 2 months. |
| 15 | I would love to see AI uptake for a wide range of equipment models. |
| 16 | I feel AI can only aid, not to fully diagnose!!! |
| 17 | I'm of the opinion that AI is inevitable, thus we need to ensure that we have a healthy relationship with the technology. |
| 18 | Already trialling AI. Still in its infancy but potential is awesome. |
| 19 | Too early to decide; if more clinical trials exist evaluating false positives/false negatives associated with diagnosing retinal |
| | conditions with AI, may reconsider. |

Table s5. Attitudes toward the use of Artificial Intelligence in an alternative clinical scenario.

Reported extent to which respondents agreed or disagreed with statements concerning the use of artificial intelligence under Clinical Scenario 2, where the artificial intelligence is used after the consultation (run overnight) and provides a second opinion on diagnosis the following morning. Allowable responses were: Strongly disagree (score 1), Disagree (score 2), Neither agree nor disagree (score 3), Agree (score 4), Strongly agree (score 5).

| Ourseties much an 8 Statement | Ranked score, mean (SD) | % (n/N) selected each category | | | | |
|---|----------------------------|--------------------------------|---------|----------|----------|----------|
| Question number & Statement | | 1 | 2 | 3 | 4 | 5 |
| In the future, I see myself using AI as | | | | | | |
| 4.1 A tool to aid the diagnosis of retinal disease | 4.1 (0.7) | 0 | 2.3 | 12.0 | 61.7 | 24.1 |
| | | (0/133) | (3/133) | (16/133) | (82/133) | (32/133) |
| 4.2 A learning tool to improve my own diagnostic | stic 4.1 (0.7) | 0 | 1.5 | 14.3 | 61.7 | 22.6 |
| abilities | | (0/133) | (2/133) | (19/133) | (82/133) | (30/133) |
| 4.3 Its increased use to aid the diagnosis of retinal | 3.9 (0.8) | 0.8 | 3.8 | 23.3 | 51.9 | 20.3 |
| disease excites me | | (1/133) | (5/133) | (31/133) | (69/133) | (27/133) |

Abbreviations: SD; Standard deviation, AI; Artificial intelligence.

Table s6. Univariate and multivariate analysis of factors influencing attitudes toward ArtificialIntelligence.

Evaluation of the association between each participant characteristic and the primary outcome question 3.1 "In the future, I see myself using AI as a tool to aid the diagnosis of retinal disease".

| Participant characteristic | Significance |
|---|--------------|
| Number of computerised systems used | P=0.004 |
| Gender | P=0.327 |
| Age | P=0.882 |
| Years practising in primary eye care | P=0.829 |
| Workplace location (Australian state/territory) | P=0.652 |
| Workplace location (geographical classification) ⁺ | P=0.746 |
| Rural vs. urban location‡ | P=0.474 |
| Workplace setting | P=0.964 |
| Number of working optometrists | P=0.568 |
| Number of patients seen daily | P=0.317 |
| Number of patients with retinal disease seen daily | P=0.644 |
| Level of accessibility to ophthalmology services | P=0.290 |
| Form of medical record system used | P=0.176 |
| Decision-making related to the use of digital health technologies | P=0.184 |
| Responsibility for IT systems | P=0.542 |

[†]Workplace locations classified according to the Australian government's Modified Monash Model for measuring remoteness and population size. The Modified Monash Model categories were grouped for analysis as follows: Major city (MM1), Large town (MM2), Rural (MM3 to MM7).

[‡] Workplace locations classified according to the Australian government's Modified Monash Model for measuring remoteness and population size. The Modified Monash Model categories were grouped for analysis as follows: Urban (MM1, MM2), Rural (MM3 to MM7).